Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

PEER REVIEW HISTORY

BMJ Open publishes all reviews undertaken for accepted manuscripts. Reviewers are asked to complete a checklist review form (see an example) and are provided with free text boxes to elaborate on their assessment. These free text comments are reproduced below. Some articles will have been accepted based in part or entirely on reviews undertaken for other BMJ Group journals. These will be reproduced where possible.

ARTICLE DETAILS

TITLE (PROVISIONAL)	A Retrospective Analysis of Long Term Outcomes Following a Single Episode of Transscleral Cyclodiode Laser Treatment in Glaucoma Patients
AUTHORS	Zhekov, Ivailo; Janjua, Razia; Shahid, Humma; Sarkies, Nicholas; Martin, Keith; White, Andrew

VERSION 1 - REVIEW

REVIEWER	Mohammed K. ElMallah, M.D. Ophthalmologist Ocala Eye
	Florida, U.S.A.
REVIEW RETURNED	10-Apr-2013

This study is a retrospective review of the efficacy of Transscleral Cyclodiode laser treatment as a first surgical intervention in patients with refractory glaucoma. Of 104 patients reviewed, 87 met inclusion criteria of complete medical records and follow-up of 3 years. Laser settings were 1500 mW for 1500 mS with average of 10 applications per quadrant. Some patients received 180 degrees of treatment while others received 360 degrees. Success was defined as IOP at last follow-up between 6-21 mmHg and IOP reduction >30%. Patients who had any additional surgical intervention were considered treatment failures. Success rate at 6 weeks was 67% and at 3 years 61%. Hypotony rate was 5%. 83.6% of patients maintained or improved their visual acuity although this data analysis was only performed on 47 patients due to lack of records.	THE STUDY	No supplemental documents attached.
first surgical intervention with 61% long term success rate as far as IOP reduction. I recommend it for acceptance. I would have the following minor recommendation of removing the word "Visual" from the title as the paper is broader is scope than what is suggested by the title as it is.	GENERAL COMMENTS	Cyclodiode laser treatment as a first surgical intervention in patients with refractory glaucoma. Of 104 patients reviewed, 87 met inclusion criteria of complete medical records and follow-up of 3 years. Laser settings were 1500 mW for 1500 mS with average of 10 applications per quadrant. Some patients received 180 degrees of treatment while others received 360 degrees. Success was defined as IOP at last follow-up between 6-21 mmHg and IOP reduction >30%. Patients who had any additional surgical intervention were considered treatment failures. Success rate at 6 weeks was 67% and at 3 years 61%. Hypotony rate was 5%. 83.6% of patients maintained or improved their visual acuity although this data analysis was only performed on 47 patients due to lack of records. Overall, this retrospective study presents TSCPC as a relatively safe first surgical intervention with 61% long term success rate as far as IOP reduction. I recommend it for acceptance. I would have the following minor recommendation of removing the word "Visual" from the title as the paper is broader is scope than what is suggested by the title as it

REVIEWER	Mr Kashif M Qureshi BSc MBBS FRCOphth Consultant Ophthalmic Surgeon
	Conquest Hospital St Leonard's On Sea East Sussex
	TN37 7RD
REVIEW RETURNED	02-May-2013

Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

- The reviewer completed the checklist but made no further comments.

VERSION 1 – AUTHOR RESPONSE

From Reviewer 1:

I recommend it for acceptance. I would have the following minor recommendation of removing the word "Visual" from the title as the paper is broader is scope than what is suggested by the title as it is. Manuscript tile revised to: 'A Retrospective Analysis of Long Term Outcomes Following a Single Episode of Transscleral Cyclodiode Laser Treatment in Glaucoma Patients'

From Reviewer 2:

(There are no comments.)

These changes are highlighted in bold in the revised manuscript. Thank you very much for your time and I look forward to hearing from you.